Literature DB >> 19775628

Cardiovascular toxicity of molecularly targeted agents.

Elizabeth L Strevel1, Lillian L Siu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19775628     DOI: 10.1016/S0959-8049(09)70046-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  9 in total

Review 1.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

Review 2.  New cast for a new era: preclinical cancer drug development revisited.

Authors:  Grit S Herter-Sprie; Andrew L Kung; Kwok-Kin Wong
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 3.  Antibody therapy of cancer.

Authors:  Andrew M Scott; Jedd D Wolchok; Lloyd J Old
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 4.  Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

5.  Patch clamp apply in cardiomyocytes derived from patient's iPS cells for individual anticancer therapy.

Authors:  Jia Zhang; Jingkun Qu; Jiansheng Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 6.  Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Authors:  Kuan-Liang Liu; Jen-Shi Chen; Shin-Cheh Chen; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2013-07       Impact factor: 2.672

7.  Assessment of the trifluoromethyl ketone functionality as an alternative zinc-binding group for selective HDAC6 inhibition.

Authors:  Yves Depetter; Silke Geurs; Flore Vanden Bussche; Rob De Vreese; Jorick Franceus; Tom Desmet; Olivier De Wever; Matthias D'hooghe
Journal:  Medchemcomm       Date:  2018-05-18       Impact factor: 3.597

8.  A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.

Authors:  Laura Goracci; Nathalie Deschamps; Giuseppe Marco Randazzo; Charlotte Petit; Carolina Dos Santos Passos; Pierre-Alain Carrupt; Claudia Simões-Pires; Alessandra Nurisso
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

9.  The growing role of precision and personalized medicine for cancer treatment.

Authors:  Paulina Krzyszczyk; Alison Acevedo; Erika J Davidoff; Lauren M Timmins; Ileana Marrero-Berrios; Misaal Patel; Corina White; Christopher Lowe; Joseph J Sherba; Clara Hartmanshenn; Kate M O'Neill; Max L Balter; Zachary R Fritz; Ioannis P Androulakis; Rene S Schloss; Martin L Yarmush
Journal:  Technology (Singap World Sci)       Date:  2019-01-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.